Last Updated: November 19, 2026

Details for Patent: 11,752,106

« Back to Dashboard


Which drugs does patent 11,752,106 protect, and when does it expire?

Patent 11,752,106 protects TRIKAFTA (COPACKAGED) and KALYDECO and is included in two NDAs.

Protection for KALYDECO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-two patent family members in thirteen countries.

Summary for Patent: 11,752,106
Title:Pharmaceutical composition and administrations thereof
Abstract:The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
Inventor(s):Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. JOHNSTON, Dragutin Knezic, Andrew G. Kuzmission, Hongren Wang
Assignee: Vertex Pharmaceuticals Inc
Application Number:US17/475,622
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,752,106
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 11,752,106

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vertex Pharms Inc TRIKAFTA (COPACKAGED) elexacaftor, ivacaftor, tezacaftor; ivacaftor GRANULE;ORAL 217660-001 Apr 26, 2023 RX Yes No 11,752,106 ⤷  Start Trial Y TREATMENT OF CF IN PATIENTS AGED 2 TO ⤷  Start Trial
Vertex Pharms Inc TRIKAFTA (COPACKAGED) elexacaftor, ivacaftor, tezacaftor; ivacaftor GRANULE;ORAL 217660-001 Apr 26, 2023 RX Yes No 11,752,106 ⤷  Start Trial Y TREATMENT OF CF WITH A COMP. OF CLAIM 1 OF US 11752106 IN CF PATIENTS AGED 2 TO ⤷  Start Trial
Vertex Pharms Inc TRIKAFTA (COPACKAGED) elexacaftor, ivacaftor, tezacaftor; ivacaftor GRANULE;ORAL 217660-002 Apr 26, 2023 RX Yes Yes 11,752,106 ⤷  Start Trial Y TREATMENT OF CF IN PATIENTS AGED 2 TO ⤷  Start Trial
Vertex Pharms Inc TRIKAFTA (COPACKAGED) elexacaftor, ivacaftor, tezacaftor; ivacaftor GRANULE;ORAL 217660-002 Apr 26, 2023 RX Yes Yes 11,752,106 ⤷  Start Trial Y TREATMENT OF CF WITH A COMP. OF CLAIM 1 OF US 11752106 IN CF PATIENTS AGED 2 TO ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.